IN2012DN00598A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00598A
IN2012DN00598A IN598DEN2012A IN2012DN00598A IN 2012DN00598 A IN2012DN00598 A IN 2012DN00598A IN 598DEN2012 A IN598DEN2012 A IN 598DEN2012A IN 2012DN00598 A IN2012DN00598 A IN 2012DN00598A
Authority
IN
India
Prior art keywords
prophylaxis
diseases
treatment
production
myomas
Prior art date
Application number
Other languages
English (en)
Inventor
Schwede Wolfgang
Klar Ulrich
Moller Carsten
Rotgeri Andrea
Bone Wilhelm
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00598(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of IN2012DN00598A publication Critical patent/IN2012DN00598A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36Antigestagens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN598DEN2012 2009-07-20 2010-07-07 IN2012DN00598A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009034362A DE102009034362A1 (de) 2009-07-20 2009-07-20 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
PCT/EP2010/004149 WO2011009531A2 (de) 2009-07-20 2010-07-07 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten

Publications (1)

Publication Number Publication Date
IN2012DN00598A true IN2012DN00598A (ru) 2015-06-12

Family

ID=43383964

Family Applications (1)

Application Number Title Priority Date Filing Date
IN598DEN2012 IN2012DN00598A (ru) 2009-07-20 2010-07-07

Country Status (48)

Country Link
US (4) US20120149670A1 (ru)
EP (4) EP2623510B1 (ru)
JP (3) JP5795312B2 (ru)
KR (2) KR101687853B1 (ru)
CN (1) CN102482317B (ru)
AR (1) AR077491A1 (ru)
AU (1) AU2010275849B2 (ru)
BR (1) BR112012001344B8 (ru)
CA (1) CA2768407C (ru)
CL (1) CL2012000166A1 (ru)
CO (1) CO6491067A2 (ru)
CR (2) CR20170091A (ru)
CU (1) CU20120012A7 (ru)
CY (3) CY1114260T1 (ru)
DE (1) DE102009034362A1 (ru)
DK (3) DK3252069T3 (ru)
DO (2) DOP2012000015A (ru)
EA (2) EA025150B1 (ru)
EC (2) ECSP12011616A (ru)
ES (3) ES2730209T3 (ru)
GT (1) GT201200012A (ru)
HK (1) HK1171456A1 (ru)
HN (1) HN2012000137A (ru)
HR (3) HRP20130558T1 (ru)
HU (2) HUE043757T2 (ru)
IL (1) IL216967B (ru)
IN (1) IN2012DN00598A (ru)
JO (2) JO3009B1 (ru)
LT (2) LT3252069T (ru)
MA (1) MA33445B1 (ru)
ME (2) ME01534B (ru)
MX (2) MX2012000930A (ru)
MY (1) MY179447A (ru)
NO (1) NO2623510T3 (ru)
NZ (2) NZ597639A (ru)
PE (2) PE20121085A1 (ru)
PL (3) PL2432798T3 (ru)
PT (3) PT2432798E (ru)
RS (1) RS52811B (ru)
SG (3) SG177519A1 (ru)
SI (3) SI2432798T1 (ru)
TN (1) TN2012000028A1 (ru)
TR (1) TR201908600T4 (ru)
TW (1) TWI505830B (ru)
UA (1) UA106502C2 (ru)
UY (1) UY32791A (ru)
WO (1) WO2011009531A2 (ru)
ZA (1) ZA201201222B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102011088270A1 (de) 2011-12-12 2013-06-13 Bayer Intellectual Property Gmbh (11ß ,17ß)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Behandlung von Morbus Charcot Marie Toot
CN105120873A (zh) 2013-04-11 2015-12-02 拜耳制药股份公司 孕酮受体拮抗剂剂型
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
US20180155388A1 (en) * 2015-05-18 2018-06-07 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulator (sprm) regimen
EP3214092A1 (en) * 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
EP3384913A1 (en) 2017-04-03 2018-10-10 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulators and stabilized estrogen level in patient
EP3701951A4 (en) * 2017-10-26 2020-09-16 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTAL SHAPE OF SELECTIVE PROGESTERONE RECEPTOR MODULATORS AND PROCESS FOR THEIR PRODUCTION
US20240139274A1 (en) 2022-03-01 2024-05-02 Altin Biosciences Corporation Crila® and egcg compositions for treatment of fibroids

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5272140A (en) 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
FR2620707B1 (fr) 1987-09-18 1989-12-08 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FR2644789B1 (fr) 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 19-nor, 3-ceto comportant une chaine en 17 aminosubstituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
ATE172469T1 (de) 1989-08-04 1998-11-15 Schering Ag 11 beta-aryl-gona-4,9-dien-3-one
US5407928A (en) 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
FR2718354B1 (fr) 1994-04-08 1996-05-03 Roussel Uclaf Application des composés antiglucocorticoïde pour la préparation de médicaments destinés à la prévention ou au traitement des manifestations liées au syndrome de sevrage des narcotiques et les compositions les renfermant.
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
ES2218556T3 (es) 1994-11-22 2004-11-16 Balance Pharmaceuticals, Inc. Metodos de contracepcion.
JP4260886B2 (ja) 1996-05-01 2009-04-30 アメリカ合衆国 新規の抗プロゲステロンとしての21―置換プロゲステロン誘導体
WO1998005679A2 (en) 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
FR2757400B1 (fr) 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010016578A1 (en) 1997-06-18 2001-08-23 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
JPH11171774A (ja) 1997-12-05 1999-06-29 Kyowa Hakko Kogyo Co Ltd 血球増多剤
PE20000129A1 (es) 1997-12-23 2000-03-11 Schering Ag 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
WO1999053924A1 (fr) 1998-04-17 1999-10-28 Kyowa Hakko Kogyo Co., Ltd. Agent analgesique
US6172052B1 (en) * 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6476079B1 (en) 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
EP1157996A1 (de) 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
US7071328B2 (en) 2000-09-18 2006-07-04 Applied Research System Ars Holding N.V. Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21 oh-6op)
US7378406B2 (en) 2000-10-18 2008-05-27 Schering Ag Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
DE10051609A1 (de) 2000-10-18 2002-05-02 Schering Ag Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
CZ299945B6 (cs) 2000-10-18 2008-12-29 Schering Aktiengesellschaft Lécivo obsahující 17alfa-fluoralkylsteroid pro lécení karcinomu prsu rezistentního vuci steroidum
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
CA2433776A1 (en) * 2001-01-09 2002-09-06 Schering Aktiengesellschaft The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
DE10221034A1 (de) 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
JP2005536463A (ja) 2002-05-03 2005-12-02 シエーリング アクチエンゲゼルシャフト 17α−フルオロアルキル−11β−ベンズアルドキシムステロイド、それらの製造方法、これらのステロイド類を含有する製剤及び医薬品製造のためのそれらの使用
US8865200B2 (en) 2004-07-09 2014-10-21 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
WO2006101009A1 (ja) 2005-03-18 2006-09-28 Hirose Engineering Co., Ltd. ナイルレッド系赤色発光化合物、及び発光素子
US20070105828A1 (en) 2005-08-19 2007-05-10 Glenmark Pharmaceuticals Limited Novel polymorph form M of mifepristone and process for its preparation
EP1862468A1 (de) 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
US20090075989A1 (en) * 2006-12-21 2009-03-19 Wolfgang Schwede Non-steroidal progesterone receptor modulators
CN101454150B (zh) 2007-03-01 2014-05-21 Prs地中海有限公司 耐uv的多层格室加固体系
EP2123279A1 (de) 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten

Also Published As

Publication number Publication date
SG177519A1 (en) 2012-02-28
LT2623510T (lt) 2017-12-11
CL2012000166A1 (es) 2012-08-31
US9717739B2 (en) 2017-08-01
EP3252069B1 (de) 2019-04-03
EA025150B1 (ru) 2016-11-30
TWI505830B (zh) 2015-11-01
KR101854059B1 (ko) 2018-05-02
DK2623510T3 (en) 2017-12-04
US20120094969A1 (en) 2012-04-19
US20150342962A1 (en) 2015-12-03
CY1114260T1 (el) 2016-08-31
JP5795312B2 (ja) 2015-10-14
JP2012533575A (ja) 2012-12-27
BR112012001344B8 (pt) 2021-05-25
IL216967A0 (en) 2012-02-29
SG10201811830PA (en) 2019-02-27
DK3252069T3 (da) 2019-06-24
EA021946B1 (ru) 2015-10-30
HUE043757T2 (hu) 2019-09-30
NZ597639A (en) 2014-04-30
AU2010275849A1 (en) 2012-02-02
EA201301263A1 (ru) 2014-08-29
RS52811B (en) 2013-10-31
ME01534B (me) 2014-04-20
CN102482317B (zh) 2014-09-17
PE20170084A1 (es) 2017-03-30
MA33445B1 (fr) 2012-07-03
PT2432798E (pt) 2013-06-28
DOP2015000276A (es) 2018-04-15
CA2768407A1 (en) 2011-01-27
GT201200012A (es) 2013-10-15
DE102009034362A1 (de) 2011-01-27
CR20120040A (es) 2012-03-12
PL2432798T3 (pl) 2013-08-30
PE20121085A1 (es) 2012-08-04
CU20120012A7 (es) 2012-07-31
US20120149670A1 (en) 2012-06-14
US8278469B2 (en) 2012-10-02
ECSP12011616A (es) 2012-02-29
AR077491A1 (es) 2011-08-31
CU24080B1 (ru) 2015-03-30
CY1119661T1 (el) 2018-04-04
ECSP18047708A (es) 2018-06-30
ES2648292T3 (es) 2017-12-29
DOP2012000015A (es) 2016-04-15
WO2011009531A2 (de) 2011-01-27
EP2432798A2 (de) 2012-03-28
MX338217B (es) 2016-04-07
DK2432798T3 (da) 2013-07-01
SI2623510T1 (sl) 2017-12-29
PL3252069T3 (pl) 2019-09-30
SI3252069T1 (sl) 2019-06-28
UY32791A (es) 2011-02-28
EA201200121A1 (ru) 2012-07-30
JP2015178522A (ja) 2015-10-08
ES2416461T3 (es) 2013-08-01
EP3272763A1 (de) 2018-01-24
KR101687853B1 (ko) 2016-12-19
EP2623510A1 (de) 2013-08-07
ME03400B (me) 2020-01-20
TR201908600T4 (tr) 2019-07-22
UA106502C2 (ru) 2014-09-10
SG10201404159VA (en) 2014-10-30
CY1121926T1 (el) 2020-10-14
WO2011009531A3 (de) 2011-04-28
JO3009B1 (ar) 2016-09-05
NO2623510T3 (ru) 2018-01-20
HRP20191049T1 (hr) 2019-09-20
CO6491067A2 (es) 2012-07-31
MX2012000930A (es) 2012-03-26
PT3252069T (pt) 2019-06-18
IL216967B (en) 2018-06-28
JO3732B1 (ar) 2021-01-31
TN2012000028A1 (en) 2013-09-19
JP2017105813A (ja) 2017-06-15
KR20160093110A (ko) 2016-08-05
CA2768407C (en) 2017-10-24
MY179447A (en) 2020-11-06
ZA201201222B (en) 2022-11-30
JP6130087B1 (ja) 2017-05-17
EP3252069A1 (de) 2017-12-06
SI2432798T1 (sl) 2013-08-30
PL2623510T3 (pl) 2018-02-28
CN102482317A (zh) 2012-05-30
HUE037339T2 (hu) 2018-08-28
ES2730209T3 (es) 2019-11-08
BR112012001344B1 (pt) 2020-09-24
HRP20171805T1 (hr) 2017-12-29
CR20170091A (es) 2018-02-06
AU2010275849B2 (en) 2014-12-18
LT3252069T (lt) 2019-06-10
KR20120046182A (ko) 2012-05-09
HK1171456A1 (en) 2013-03-28
US20170202857A1 (en) 2017-07-20
PT2623510T (pt) 2017-11-24
NZ623417A (en) 2015-10-30
HN2012000137A (es) 2015-05-04
BR112012001344A2 (pt) 2016-03-15
HRP20130558T1 (hr) 2013-07-31
TW201105331A (en) 2011-02-16
EP2432798B1 (de) 2013-04-03
EP2623510B1 (de) 2017-08-23
US10155004B2 (en) 2018-12-18

Similar Documents

Publication Publication Date Title
JO3732B1 (ar) مشتقات 17-هيدروكسي-17بنتافلوروإيثيل-إسترا-4،9(10)-دين-11-أريل، طريقة لإنتاجها واستخدامها في معالجة الأمراض
WO2011009529A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten
WO2011009530A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9 (10)-dien-11-acyloxyalkylenphenyl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten
WO2011098437A3 (de) Progesteronrezeptorantagonisten
WO2011009534A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten
PH12017502100A1 (en) Selective progesterone receptor modulator (sprm) regimen
MX369520B (es) Uso de una combinación farmacéutica para el tratamiento de fibromas uterinos.
PH12015502326A1 (en) Progesterone receptor antagonist dosage form
NZ612295A (en) Novel 19-nor-steroids and their use for treating progesterone-dependent conditions
UA51785U (ru) Способ лечения сочетанных дисгормональных нарушений у женщин репродуктивного возраста